Skip to main content
Clinical trial efficacy data
Navbar Image
Clinical trial efficacy data
This site is intended only for US healthcare professionals.

Clinical trial efficacy data

Reduced risk of neutropenia in clinical trials1-4

  • Fewer white blood cell-related events from chemotherapy in patients receiving COSELA in clinical trials, including1-4:
    • Severe neutropenia (primary and exploratory endpoints)
    • Grade 4 neutropenia in cycle 1 (primary and exploratory endpoints)
    • Febrile neutropenia (secondary and exploratory endpoints)
    • Need for G-CSF administration (secondary and exploratory endpoints)
  • In treatment groups receiving COSELA, fatal adverse events included pneumonia, respiratory failure, acute respiratory failure, hemoptysis, and cerebrovascular accident

1L=1st-line; 2L=2nd-line; 3L=3rd-line; G-CSF=granulocyte colony-stimulating factor.

a
Multiplicity-adjusted P  value (P<0.0001); aRR=0.038 (95% confidence interval: 0.008, 0.195).1
b
Multiplicity-adjusted P  value (P<0.0001); mean difference -3.6 (95% confidence interval: -4.9, -2.3).1
c
Multiplicity-adjusted P  value (P<0.0686); aRR=0.646 (95% confidence interval: 0.403, 1.034).1
d
Study 2 was a proof-of-concept study with the primary objectives of assessing safety and tolerability; efficacy objectives were secondary or exploratory.2